Spots Global Cancer Trial Database for Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Official Title: A Phase 2 Study of Regorafenib in Metastatic Gastrointestinal Stromal Tumours With C-KIT exon17 Mutation
Study ID: NCT02606097
Conditions
Interventions
Study Description
Brief Summary: The main purpose of this study is to examine whether regorafenib treatment can help people with gastrointestinal stromal tumours (GIST) and have gene mutation on c-kit exon 17. The safety of regorafenib treatment is also examined.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chang Gung Memorial Hospital, Taoyuan, , Taiwan
Contact Details
Name: Chun-Nan Yeh, MD
Affiliation: Professor and Chief, Department of Surgery
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
